Beijing Leadman Biochemistry reports Q3 2025 net loss amid revenue drop

Beijing Leadman Biochemistry announced its third-quarter results for 2025, with total operating revenue for the nine months ended September 30, 2025, reaching 252,243,444.78 yuan, a 10.49% decrease year-over-year. The company reported a net loss attributable to shareholders of 7,134,797.31 yuan for the nine-month period, a substantial decline of 765.83% compared to the previous year.

The company’s total assets stood at 1,809,089,327.52 yuan at the end of the third quarter, a slight decrease of 0.73% from the end of last year. Cash flow from operating activities significantly dropped by 79.26% to 9,681,515.67 yuan. This was attributed to lower received payments for goods and higher payments for raw materials.

A key development for the company is its ongoing asset restructuring, with a planned acquisition of up to 70% of Beijing Xianrui Biotechnology Co. The company is currently engaged in due diligence and negotiations, with formal transaction documents yet to be signed.